SMARCB1 regulates the hypoxic stress response in sickle cell trait
Authors:
- Melinda SoeungMSMelinda Soeung
- Luigi PerelliLPLuigi Perelli
- Ziheng ChenZCZiheng Chen
- Eleonora DondossolaEDEleonora Dondossola
- I-Lin HoIHI-Lin Ho
- Federica CarboneFCFederica Carbone
- Li ZhangLZLi Zhang
- Hania KhanHKHania Khan
- Courtney N. LeCLCourtney N. Le
- Cihui ZhuCZCihui Zhu
- Michael D. PeoplesMPMichael D. Peoples
- Ningping FengNFNingping Feng
Open Access
- 15 May 2023
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (21)
Abstract
Renal medullary carcinoma (RMC) is an aggressive kidney cancer that almost exclusively develops in individuals with sickle cell trait (SCT) and is always characterized by loss of the tumor suppressor SMARCB1 . Because renal ischemia induced by red blood cell sickling exacerbates chronic renal medullary hypoxia in vivo, we investigated whether the loss of SMARCB1 confers a survival advantage under the setting of SCT. Hypoxic stress, which naturally occurs within the renal medulla, is elevated under the setting of SCT. Our findings showed that hypoxia-induced SMARCB1 degradation protected renal cells from hypoxic stress. SMARCB1 wild-type renal tumors exhibited lower levels of SMARCB1 and more aggressive growth in mice harboring the SCT mutation in human hemoglobin A (HbA) than in control mice harboring wild-type human HbA. Consistent with established clinical observations, SMARCB1-null renal tumors were refractory to hypoxia-inducing therapeutic inhibition of angiogenesis. Further, reconstitution of SMARCB1 restored renal tumor sensitivity to hypoxic stress in vitro and in vivo. Together, our results demonstrate a physiological role for SMARCB1 degradation in response to hypoxic stress, connect the renal medullary hypoxia induced by SCT with an increased risk of SMARCB1-negative RMC, and shed light into the mechanisms mediating the resistance of SMARCB1-null renal tumors against angiogenesis inhibition therapies.Keywords
Funding Information
- Translational Research Partnership (KC200096P1)
- Division of Cancer Prevention, National Cancer Institute (NCI P30CA016672)
This publication has 36 references indexed in Scilit:
- BRG1 and BRM Chromatin-Remodeling Complexes Regulate the Hypoxia Response by Acting as Coactivators for a Subset of Hypoxia-Inducible Transcription Factor Target GenesMolecular and Cellular Biology, 2013
- Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarizationNature, 2013
- Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypassNature Cell Biology, 2012
- The nuclear localization of SWI/SNF proteins is subjected to oxygen regulationCell & Bioscience, 2012
- Methods for Quantification of in vivo Changes in Protein Ubiquitination following Proteasome and Deubiquitinase InhibitionMolecular & Cellular Proteomics, 2012
- A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory RolesMolecular & Cellular Proteomics, 2011
- The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoProceedings of the National Academy of Sciences, 2011
- A robust and high-throughput Cre reporting and characterization system for the whole mouse brainNature Neuroscience, 2009
- Correction of sickle cell disease by homologous recombination in embryonic stem cellsBlood, 2006
- Generation of a Stable Cell Line Producing High-Titer Self-Inactivating Lentiviral VectorsMolecular Therapy, 2001